Scholarlink

<p>Dysfunctional autophagy, a key cellular cleaning process, is a key driver of brain ageing and neurodegenerative diseases such as Alzheimer’s disease (AD). However, developing effective treatments by enhancing autophagy has been challenging, as most known compounds act through the broad mTOR pathway, risking side effects, and few can effectively penetrate the brain. To address this, we developed DeepDrugDiscovery—a mechanism-aware, AI-powered screening platform incorporating ADMET and blood–brain barrier penetrability predictions. Here we show that this platform successfully identified novel, mTOR-independent autophagy enhancers, with two lead compounds demonstrating an ability to cross the blood–brain barrier, clear AD-related protein aggregates and restore memory function in worm and mouse AD models. By releasing DeepDrugDiscovery as an open-source, modular tool, we offer a user-friendly AI platform that enables customized therapeutic screening. Our work establishes a scalable, AI-driven pipeline that integrates cross-species validation to rapidly discover mechanism-based therapeutics for diseases with high unmet medical need.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

DeepDrugDiscovery identifies blood–brain barrier permeable autophagy enhancers for Alzheimer’s disease

  • 期刊论文

  • 发表日期：

    2026年4月24日

查看全文
  • Yu Dong,
  • Xianglu Xiao,
  • Xu-Xu Zhuang,
  • Wenfan Wu,
  • Zi-Ying Wang,
  • Shuang Zhang,
  • Jin-Tao Li,
  • Ke Zhang,
  • Wen-Yu Fu,
  • Jun-Ming Chen,
  • Shi Hang Xiong,
  • Shenglong Deng,
  • Krinos Li,
  • Chao Ma,
  • Wangzhen Jin,
  • Xurui Jin,
  • Qiwei Cai,
  • Han-Ming Shen,
  • Min Li,
  • Huanxing Su,
  • Jian-Bo Wan,
  • Hua Yu,
  • Defang Ouyang,
  • Keqiang Ye,
  • Evandro F. Fang,
  • Chris Soon Heng Tan,
  • Guang Yang,
  • Zhangming Niu,
  • Jia-Hong Lu

摘要

Dysfunctional autophagy, a key cellular cleaning process, is a key driver of brain ageing and neurodegenerative diseases such as Alzheimer’s disease (AD). However, developing effective treatments by enhancing autophagy has been challenging, as most known compounds act through the broad mTOR pathway, risking side effects, and few can effectively penetrate the brain. To address this, we developed DeepDrugDiscovery—a mechanism-aware, AI-powered screening platform incorporating ADMET and blood–brain barrier penetrability predictions. Here we show that this platform successfully identified novel, mTOR-independent autophagy enhancers, with two lead compounds demonstrating an ability to cross the blood–brain barrier, clear AD-related protein aggregates and restore memory function in worm and mouse AD models. By releasing DeepDrugDiscovery as an open-source, modular tool, we offer a user-friendly AI platform that enables customized therapeutic screening. Our work establishes a scalable, AI-driven pipeline that integrates cross-species validation to rapidly discover mechanism-based therapeutics for diseases with high unmet medical need.